Rhythm Pharmaceuticals, Inc.

NasdaqGM:RYTM Stock Report

Market Cap: US$7.1b

Rhythm Pharmaceuticals Management

Management criteria checks 2/4

Rhythm Pharmaceuticals' CEO is David Meeker, appointed in Jul 2020, has a tenure of 5.5 years. total yearly compensation is $14.66M, comprised of 5% salary and 95% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth $21.60M. The average tenure of the management team and the board of directors is 5.2 years and 10.2 years respectively.

Key information

David Meeker

Chief executive officer

US$14.7m

Total compensation

CEO salary percentage5.05%
CEO tenure5.5yrs
CEO ownership0.3%
Management average tenure5.2yrs
Board average tenure10.2yrs

Recent management updates

Recent updates

Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster

Dec 11

The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 07
The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%

Jul 10
Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%

Rhythm Pharmaceuticals (NASDAQ:RYTM) Has Debt But No Earnings; Should You Worry?

Jun 25
Rhythm Pharmaceuticals (NASDAQ:RYTM) Has Debt But No Earnings; Should You Worry?
User avatar

Label Expansion And Global Healthcare Will Widen Future Market Opportunities

Label expansion and global commercialization of IMCIVREE are set to drive substantial revenue growth and broaden market reach.

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up

May 04
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Apr 08

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Feb 25

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Jan 19
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Rhythm Pharmaceuticals: A Key Year Ahead

Dec 06

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Sep 22

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Aug 29

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Jun 12

Rhythm Pharmaceuticals: Action Too Specific

Feb 23

CEO Compensation Analysis

How has David Meeker's remuneration changed compared to Rhythm Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$198m

Jun 30 2025n/an/a

-US$188m

Mar 31 2025n/an/a

-US$174m

Dec 31 2024US$15mUS$740k

-US$265m

Sep 30 2024n/an/a

-US$262m

Jun 30 2024n/an/a

-US$261m

Mar 31 2024n/an/a

-US$274m

Dec 31 2023US$7mUS$705k

-US$185m

Sep 30 2023n/an/a

-US$186m

Jun 30 2023n/an/a

-US$182m

Mar 31 2023n/an/a

-US$181m

Dec 31 2022US$3mUS$652k

-US$181m

Sep 30 2022n/an/a

-US$181m

Jun 30 2022n/an/a

-US$176m

Mar 31 2022n/an/a

-US$166m

Dec 31 2021US$6mUS$630k

-US$70m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$15mUS$262k

-US$134m

Sep 30 2020n/an/a

-US$132m

Jun 30 2020n/an/a

-US$134m

Mar 31 2020n/an/a

-US$146m

Dec 31 2019US$287kn/a

-US$141m

Compensation vs Market: David's total compensation ($USD14.66M) is above average for companies of similar size in the US market ($USD8.28M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Meeker (71 yo)

5.5yrs
Tenure
US$14,663,742
Compensation

Dr. David P. Meeker, MD, is Member of Advisory Board of Mitotherapeutix, LLC. Dr. Meeker had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 20...

Leadership Team

NamePositionTenureCompensationOwnership
David Meeker
Chairman5.5yrsUS$14.66m0.30%
$ 21.6m
Hunter Smith
CFO & Treasurer8.5yrsUS$5.05m0.18%
$ 12.5m
Joseph Shulman
Chief Technical Officer5.5yrsUS$3.41m0.013%
$ 910.8k
Yann Mazabraud
Executive VP & Head of International5.3yrsUS$5.62m0.056%
$ 4.0m
Jennifer Lee
Executive VP & Head of North America5.2yrsUS$4.32m0.0088%
$ 627.2k
Christopher German
Corporate Controller & Principal Accounting Officer2.8yrsno data0.0014%
$ 98.6k
Alastair Garfield
Chief Scientific Officer1.5yrsno data0.0047%
$ 334.3k
David Connolly
Head of Investor Relations & Corporate Communicationsno datano datano data
Jim Flaherty
Senior VP & General Counsel5.2yrsno datano data
Sarah Ryan
Vice President of Sales & Marketingno datano datano data
Pamela Cramer
Chief Human Resources Officer4.5yrsno data0.031%
$ 2.2m
Elisabeth Cronert-Bendell
Senior VP & Head of Strategy3.9yrsno datano data
5.2yrs
Average Tenure
51.5yo
Average Age

Experienced Management: RYTM's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Meeker
Chairman10.2yrsUS$14.66m0.30%
$ 21.6m
Jennifer Good
Independent Director6.6yrsUS$621.84k0.010%
$ 749.3k
David W. McGirr
Independent Director10.2yrsUS$639.34k0.010%
$ 749.3k
Edward Mathers
Lead Independent Director12.8yrsUS$659.34k0.019%
$ 1.4m
Lynn Tetrault
Independent Director5.1yrsUS$632.01k0.010%
$ 749.3k
Christophe Jean
Independent Director10.8yrsUS$624.34k0.010%
$ 749.3k
William Chin
Member of Scientific Advisory Boardno datano datano data
Elizabeth Stoner
Member of Scientific Advisory Boardno datano datano data
Michael Camilleri
Member of Scientific Advisory Boardno datano datano data
Lee Kaplan
Chairman of Scientific Advisory Boardno datano datano data
John Amatruda
Member of Scientific Advisory Boardno datano datano data
Stuart Arbuckle
Independent Director6.5yrsUS$625.68k0.010%
$ 749.3k
10.2yrs
Average Tenure
70.5yo
Average Age

Experienced Board: RYTM's board of directors are seasoned and experienced ( 10.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/02 10:01
End of Day Share Price 2025/12/31 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rhythm Pharmaceuticals, Inc. is covered by 24 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Whitney IjemCanaccord Genuity
Samantha Lynn SemenkowCitigroup Inc